Drug intelligence / Profile preview

AD201

Development stage: Unknown
Lead developer: Shenzhen Zero-One Life Technology
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

AD201 is a topical live biotherapeutic product (LBP) being developed by Shenzhen 01 Life Technology Co., Ltd (01Life) for the treatment of atopic dermatitis. As a microbiome-based therapy, it is designed to modulate the skin microbiome, potentially restoring healthy microbial balance to alleviate symptoms such as inflammation and pruritus. The drug candidate has completed Phase 1 clinical development, where it was evaluated for safety, tolerability, and preliminary efficacy. AD201 is part of a broader pipeline of microbiome-derived therapies from 01Life that utilize both live bacteria and recombinant LBP technology platforms. According to company pipeline information, the product is currently at the license-out stage following the completion of its initial clinical assessment.

Beyond the preview

Go deeper on AD201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD201.

Explore the full profile